Literature DB >> 27785783

The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.

Francisco Perea1, Mónica Bernal1, Abel Sánchez-Palencia2, Javier Carretero1, Cristina Torres1, Clara Bayarri2, Mercedes Gómez-Morales3, Federico Garrido1,4,5, Francisco Ruiz-Cabello1,4,5.   

Abstract

We wanted to analyze whether tumor HLA class I (HLA-I) expression influences the pattern of the immune cell infiltration and stromal cell reaction in the tumor microenvironment. Tumor tissues obtained from 57 patients diagnosed with lung carcinomas were analyzed for HLA expression and leukocyte infiltration. 28 patients out of the 57 were completely negative for HLA-I expression (49.1%) or showed a selective HLA-A locus downregulation (three patients, 5.2%). In 26 out of 57 tumors (47.8%) we detected a positive HLA-I expression but with a percentage of HLA-I negative cells between 10 and 25%. The HLA-I negative phenotype was produced by a combination of HLA haplotype loss and a transcriptional downregulation of β2-microglobulin (β2-m) and LMP2 and LMP7 antigen presentation machinery genes. The analysis and localization of different immune cell populations revealed the presence of two major and reproducible patterns. One pattern, which we designated "immune-permissive tumor microenvironment (TME)," was characterized by positive tumor HLA-I expression, intratumoral infiltration with cytotoxic T-CD8+ cells, M1-inflammatory type macrophages, and a diffuse pattern of FAP+ cancer-associated fibroblasts. In contrast, another pattern defined as "non-immune-permissive TME" was found in HLA-I negative tumors with strong stromal-matrix interaction, T-CD8+ cells surrounding tumor nests, a dense layer of FAP+ fibroblasts and M2/repair-type macrophages. In conclusion, this study revealed marked differences between HLA class I-positive and negative tumors related to tissue structure, the composition of leukocyte infiltration and stromal response in the tumor microenvironment.
© 2016 UICC.

Entities:  

Keywords:  HLA class I loss; immune escape; lung cancer; tumor infiltrating lymphocytes

Mesh:

Substances:

Year:  2016        PMID: 27785783     DOI: 10.1002/ijc.30489

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  34 in total

1.  Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.

Authors:  Lina Such; Fang Zhao; Derek Liu; Beatrice Thier; Vu Thuy Khanh Le-Trilling; Antje Sucker; Christoph Coch; Natalia Pieper; Sebastian Howe; Hilal Bhat; Halime Kalkavan; Cathrin Ritter; Robin Brinkhaus; Selma Ugurel; Johannes Köster; Ulrike Seifert; Ulf Dittmer; Martin Schuler; Karl S Lang; Thomas A Kufer; Gunther Hartmann; Jürgen C Becker; Susanne Horn; Soldano Ferrone; David Liu; Eliezer M Van Allen; Dirk Schadendorf; Klaus Griewank; Mirko Trilling; Annette Paschen
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

2.  The evolving understanding of immunoediting and the clinical impact of immune escape.

Authors:  Caroline E McCoach; Trever G Bivona
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.

Authors:  Shin Ishihara; Takeshi Iwasaki; Kenichi Kohashi; Kengo Kawaguchi; Yu Toda; Toshifumi Fujiwara; Nokitaka Setsu; Makoto Endo; Yoshihiro Matsumoto; Yasuharu Nakashima; Yoshinao Oda
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-23       Impact factor: 4.553

4.  Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor.

Authors:  Fan Fei; Liang Rong; Nan Jiang; Alan S Wayne; Jianming Xie
Journal:  Mol Ther       Date:  2021-11-18       Impact factor: 11.454

5.  CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma.

Authors:  Anupam Kumar; Esraa Mohamed; Schuyler Tong; Katharine Chen; Joydeep Mukherjee; Yunita Lim; Cynthia M Wong; Zoe Boosalis; Anny Shai; Russell O Pieper; Nalin Gupta; Arie Perry; Andrew W Bollen; Annette M Molinaro; David A Solomon; Joseph T C Shieh; Joanna J Phillips
Journal:  Clin Cancer Res       Date:  2022-07-01       Impact factor: 13.801

6.  HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.

Authors:  María A Garrido; Teresa Rodriguez; Svitlana Zinchenko; Isabel Maleno; Francisco Ruiz-Cabello; Ángel Concha; Nicolás Olea; Federico Garrido; Natalia Aptsiauri
Journal:  Immunogenetics       Date:  2018-08-25       Impact factor: 2.846

Review 7.  Cancer immune escape: MHC expression in primary tumours versus metastases.

Authors:  Federico Garrido; Natalia Aptsiauri
Journal:  Immunology       Date:  2019-10-01       Impact factor: 7.397

Review 8.  Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer.

Authors:  Lynette M Sholl
Journal:  Mod Pathol       Date:  2021-10-04       Impact factor: 7.842

9.  Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy.

Authors:  Evelien Schaafsma; Chloe M Fugle; Xiaofeng Wang; Chao Cheng
Journal:  Br J Cancer       Date:  2021-05-12       Impact factor: 9.075

10.  Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer.

Authors:  Jennifer L Schehr; Nan Sethakorn; Zachery D Schultz; Camila I Hernandez; Rory M Bade; Diego Eyzaguirre; Anupama Singh; David J Niles; Leslie Henderson; Jay W Warrick; Scott M Berry; Kaitlin E Sundling; David J Beebe; Ticiana A Leal; Joshua M Lang
Journal:  Biomark Res       Date:  2022-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.